Multiple Myeloma
Conditions
Keywords
multiple myeloma, isatuximab, RCT
Brief summary
This is a multicenter, prospective, randomized controlled trial designed to compare the quadruplet regimen of isatuximab, bortezomib, lenalidomide, and dexamethasone (Isa-VRD) with the standard triplet regimen (VRD) in newly diagnosed, transplant-ineligible patients with high-risk multiple myeloma (HRMM). Primary Hypothesis: The addition of isatuximab to VRD will significantly improve the MRD negativity rate at 12 months compared to VRD alone in HR-NDMM patients. Secondary Hypotheses: Isa-VRD will lead to higher overall response rates (ORR), deeper responses, and improved progression-free survival (PFS) and overall survival (OS). The safety profile of Isa-VRD will be manageable and consistent with the known safety profiles of its individual components.
Detailed description
This is a prospective, multicenter, randomized, open-label, Phase IIIb clinical trial. The study aims to evaluate the efficacy and safety of the quadruplet regimen Isatuximab in combination with Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRD) compared to the standard triplet regimen of Bortezomib, Lenalidomide, and Dexamethasone (VRD) in newly diagnosed high-risk multiple myeloma (HRMM) patients who are not candidates for autologous stem cell transplantation. A total of 117 participants will be enrolled and randomly assigned in a 2:1 ratio to receive either Isa-VRD (78 participants) or VRD (39 participants). The study consists of an induction-consolidation phase (cycles 1-12) followed by a maintenance phase (from cycle 13 onwards until disease progression or unacceptable toxicity). The primary endpoint is the rate of minimal residual disease (MRD) negativity in the bone marrow assessed by flow cytometry at 12 months of treatment. Key secondary endpoints include MRD negativity rate at 18 months, objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety profile.
Interventions
Participants in this group will receive the quadruplet induction-consolidation regimen of Isatuximab in combination with Bortezomib, Lenalidomide, and Dexamethasone (Isa-VRD) for 12 cycles (each cycle is 28 days). This will be followed by a maintenance therapy with Isatuximab, Bortezomib and Lenalidomide until disease progression or unacceptable toxicity.
Participants in this group will receive the standard triplet induction-consolidation regimen of Bortezomib, Lenalidomide, and Dexamethasone (VRD) for 12 cycles (each cycle is 28 days). This will be followed by a maintenance therapy with Bortezomib and Lenalidomide until disease progression or unacceptable toxicity.
Sponsors
Handan Central Hospital
Inner Mongolia People's Hospital
The Affiliated Hospital of Qingdao University
Hebei Medical University Third Hospital
North China University of Science and Technology
China-Japan Union Hospital, Jilin University
Cangzhou Central Hospital
Yantai Yuhuangding Hospital
Shengjing Hospital
Second Hospital of Shanxi Medical University
Beijing Chao Yang Hospital
Beijing Jishuitan Hospital
Henan Cancer Hospital
Beijing Hospital
Xuanwu Hospital, Beijing
Shandong Cancer Hospital and Institute
Peking Union Medical College Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Newly diagnosed Multiple myeloma ，meeting the IMWG 2025 definition of high-risk MM (any one criterion): (1) Del(17p) (\>20% of plasma cells) and/orTP53 mutation or（2）One of these translocations cooccurring with 1q+ and/or del(1p32) , or t(4;14), or t(14;16), or t(14;20) or （3） Monoallelic del(1p32) along with 1q+ or biallelic del(1p32) or（4） High β2M (\>5.5 mg/dL) with normal creatinine (\<1.2 mg/dL) or（5）Or presents with any other high-risk feature: meeting diagnostic criteria for primary plasma cell leukemia or presence of extramedullary plasmacytoma at baseline; * Age ≥18 years and ≤80 years; * Not eligible for autologous hematopoietic stem cell transplantation or has declined transplantation for other reasons. * ECOG score 0-2 * Expected survival time \> 3 months * Sufficient organ function is defined as follows: absolute neutrophil count ≥ 1.0×10\^9/L, platelet count ≥ 50×10\^9/L (when the proportion of bone marrow plasma cells is \<50%), hemoglobin ≥ 7.5 g/dL; total bilirubin ≤ 1.5 times the upper limit of normal, aspartate aminotransferase and alanine aminotransferase ≤ 2.5 times the upper limit of normal; creatinine clearance rate ≥ 30 mL/min; left ventricular ejection fraction ≥ 50%. * Fertile female or male subjects must agree to take effective contraceptive measures during the study period and within the specified time after the last administration. * Voluntarily participated in this study, signed the informed consent form, had good compliance, and was cooperative during the follow-up.
Exclusion criteria
* Prior systemic anti-myeloma therapy; * Viral infections including HBV, HCV, HIV, etc.; * Serious cardiovascular and cerebrovascular diseases, such as: within 6 months before screening, myocardial infarction, unstable angina pectoris, severe arrhythmia, New York Heart Function Classification III-IV grade, or left ventricular ejection fraction \<50%. * Severe neurological or mental disorders that affect the ability to give informed consent or comply with the protocol. * Had an allergic reaction to isatuximab, bortezomib, lenalidomide, dexamethasone or any excipients * Pregnant or lactating women. * Participated in other interventional clinical studies, or had received other anti-tumor treatments within the specified time before the first administration of this study. * The researcher believes that there are any other circumstances unsuitable for participating in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| MRD negativity rate at 12 months | at 12 months post-treatment initiation | MRD negativity rate at 12 months post-treatment initiation, assessed by EuroFlow (NGF) with a sensitivity of at least 10-5 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MRD negativity rate at 18 months | at 18 months post-treatment initiation | MRD negativity rate at 18 months post-treatment initiation, assessed by EuroFlow (NGF) with a sensitivity of at least 10-5 |
| Progression-free survival | From date of enrollment until the date of first documented progression | from enrollment to first disease progression |
| overall survival | : From date of enrollment until the date of death from any cause | from enrollment to death with follow-up |
| Overall response rate | From randomization until the end of the induction-consolidation phase | The proportion of participants who achieve a predefined response or better according to the International Myeloma Working Group (IMWG) uniform response criteria. The response categories included in the ORR calculation are: stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR). ORR will be calculated as (number of participants with sCR+CR+VGPR+PR) / (total number of response-evaluable participants) \* 100%. |
Countries
China
Contacts
Primary ContactZhuang Junling, PhD.MD
Backup ContactFujing Zhang, MD.
Outcome results
None listed